Gongyan Chen

机构：Harbin Medical University, Third Affiliated Hospital of Harbin Medical University · ORCID：0009-0003-8805-8812

发表论文 123 篇 · 总被引 10164 次 · h-index 33

代表论文

• Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study (2023 · The Lancet Respiratory Medicine · 被引 75)
• Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS) (2024 · 癌症：英文版 · 被引 28)
• Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial (2024 · The Lancet Respiratory Medicine · 被引 21)
• HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer (2023 · Clinical Cancer Research · 被引 14)
• Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 13)
• Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study (2024 · The Lancet Respiratory Medicine · 被引 9)